01228 CANBRIDGE-B
- 0.340
- -0.005-1.45%
CANBRIDGE-B News
CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Revenues
The CANbridge Pharmaceuticals Inc. (HKG:1228) share price has fared very poorly over the last month, falling by a substantial 26%. The recent drop completes a disastrous twelve months for sharehold
北海康成-B：2023 年報
Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials
Canbridge Pharmaceuticals (HKG:1228) announced that it would discontinue the development of its new glioblastoma multiforme drug CAN008 after Phase II clinical trials, according to a Monday filing on
Beihai Kangcheng-B (01228) decided to discontinue development and further testing of CAN008 in the field of glioblastoma
Beihai Kangcheng-B (01228) announced that CAN008 in patients newly diagnosed with glioblastoma based on treatment...
Beihai Kangcheng-B (01228) grants 2.7 million share options and 2.7 million restricted share units
Beihai Kangcheng-B (01228) issued an announcement. On April 9, 2024, the company purchased after sales in accordance with the initial public development...
Revenues Working Against CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Following 27% Dive
To the annoyance of some shareholders, CANbridge Pharmaceuticals Inc. (HKG:1228) shares are down a considerable 27% in the last month, which continues a horrid run for the company. For any long-ter
Beihai Kangcheng-B (01228) announced annual results. Shareholders' losses amounted to 379 million yuan, a year-on-year decrease of 21.64%
Beihai Kangcheng-B (01228) announced results for the year ended December 31, 2023, with revenue of 103 million...
CANBRIDGE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Beihai Kangcheng-B (01228.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui March 18 | Beihai Kangcheng-B (01228.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to consider and approve (among other things) the results and announcements of the company and its subsidiaries for the year ended December 31, 2023.
CANBRIDGE-B: DATE OF BOARD MEETING
CANbridge Pharmaceuticals Grants Share Options, Restricted Shares
CANbridge Pharmaceuticals (HKG:1228) granted 10,115,000 share options to 27 participants of its post-IPO share option scheme and 3,636,000 restricted share units to 19 participants on Wednesday, a Thu
Beihai Kangcheng-B granted a total of 1.115 million share options
Beihai Kangcheng-B (01228) announced that on February 7, 2024, the company granted a total of 1.115 million share options to 27 share option grantees in accordance with the initial public offering after-sales share option plan, subject to acceptance by the share option grantor before it can be implemented. The exercise price of the share options granted was HK$0.41 per share.
Beihai Kangcheng-B (01228.HK) grants share options and restricted share units
Gelonghui, Feb. 8, 丨 Beihai Kangcheng-B (01228.HK) announced that on February 7, 2024, the company granted a total of 1.115 million share purchase rights to 27 share purchase rights under the initial public offering after-sales share option plan and granted a total of 3.636 million restricted share units to 19 restricted share unit grantees under the post-initial public offering restricted share unit plan.
Beihai Kangcheng-B (01228) fell 15.90% and now reports 0.345 yuan, a 52-week low
As of 15:14, Beihai Kangcheng-B (01228) fell 15.90% from yesterday's closing price and now reports a 52-week low of $0.345; the trading volume is 50,000 shares, with a turnover of HK$0.21 million.
Beihai Kangcheng-B [01228] now reports HK$0.345, a decrease of 15.85%
As of 15:14, Beihai Kangshing-B [01228] reported HK$0.345, down HK$0.065 or 15.85% from yesterday's closing price, with a turnover of HK$0.21 million. Today's high price was HK$0.43 and the lowest price was HK$0.345. Based on yesterday's closing price, the 10-day average price was HK$0.49 and the 50-day average price was HK$0.80. The current price-earnings ratio was -0.32 times, and the 14-day strength and weakness index reported 6.25.
Beihai Kangcheng-B (01228) fell 12.80% to 0.375 yuan, a 52-week low
As of 16:08, Beihai Kangcheng-B (01228) is down 12.80% from yesterday's closing price and now reports $0.375, a 52-week low; the trading volume is 124,400 shares, with a turnover of HK$45,800.
Hokkai Yasunari-B (01228): Derek Paul Di Rocco resigns as non-executive director
According to the Zhitong Finance App, Beihai Kangcheng-B (01228) announced that since Dr. Derek Paul Di Rocco plans to spend more time on his personal affairs, he has resigned as a non-executive director of the company and a member of the nomination and corporate governance committee, effective November 23, 2023. Following the resignation of Dr. Di Rocco, he ceased to serve as a member of the Nomination and Corporate Governance Committee, effective from the effective date.
CANBRIDGE-B: INTERIM REPORT 2023
Beihai Kangcheng-B (01228) clomaxibate oral solution to be included in priority review
On September 21, according to the CDE official website, it is proposed to include Beihai Kangcheng-B (01228) clomaxibate oral solution in the priority review.
CANbridge Pharmaceuticals' H1 Attributable Loss Narrows
CANbridge Pharmaceuticals' (HKG:1228) attributable loss narrowed to 218.2 million yuan, or 0.51 yuan per share, in the first half, from 249 million yuan, or 0.59 yuan per share, in the year-ago period
Analysis
Price Target
No Data
